Isthmus Partners LLC Boosts Holdings in HCA Healthcare, Inc. $HCA

Isthmus Partners LLC raised its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,936 shares of the company’s stock after purchasing an additional 235 shares during the period. HCA Healthcare accounts for approximately 1.7% of Isthmus Partners LLC’s investment portfolio, making the stock its 19th biggest holding. Isthmus Partners LLC’s holdings in HCA Healthcare were worth $14,150,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Cheviot Value Management LLC purchased a new stake in shares of HCA Healthcare during the first quarter worth about $26,000. Saudi Central Bank purchased a new position in shares of HCA Healthcare in the first quarter worth $26,000. WPG Advisers LLC acquired a new position in shares of HCA Healthcare in the 1st quarter valued at $27,000. Ameriflex Group Inc. acquired a new stake in HCA Healthcare during the 2nd quarter worth about $27,000. Finally, Chung Wu Investment Group LLC acquired a new position in shares of HCA Healthcare in the second quarter valued at about $27,000. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $502.98 on Tuesday. The firm has a market capitalization of $114.78 billion, a price-to-earnings ratio of 19.44, a price-to-earnings-growth ratio of 1.38 and a beta of 1.41. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $520.00. The business’s 50 day moving average price is $453.97 and its 200-day moving average price is $407.49.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The business had revenue of $19.16 billion during the quarter, compared to analysts’ expectations of $18.55 billion. During the same quarter in the previous year, the company earned $4.90 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, sell-side analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a $0.72 dividend. The ex-dividend date is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is presently 11.13%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HCA shares. Barclays upped their price objective on shares of HCA Healthcare from $445.00 to $494.00 and gave the company an “overweight” rating in a report on Monday, October 27th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of HCA Healthcare in a research report on Monday, November 24th. Raymond James Financial set a $525.00 target price on HCA Healthcare in a research note on Monday, October 27th. Sanford C. Bernstein reiterated a “market perform” rating and set a $417.00 price target on shares of HCA Healthcare in a research report on Monday, October 27th. Finally, Robert W. Baird raised their price objective on shares of HCA Healthcare from $380.00 to $423.00 and gave the stock a “neutral” rating in a research note on Thursday, August 14th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $474.53.

Insider Transactions at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares in the company, valued at $1,652,105.73. This represents a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares of the company’s stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.30% of the stock is owned by corporate insiders.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.